Pediatric glioma patients typically respond poorly to immune checkpoint inhibitors (ICI) due to an immune suppressive environment, low tumor mutational burden (TMB), low MHC expression, and heterogeneity of mismatch repair deficient (MMRD) cells within glioma tumors. However, a subset of MMRD-driven hypermutated pediatric glioma patients may benefit from ICI therapy. In this open-label, single-arm pilot study, Das and colleagues assessed the safety and efficacy of the anti-PD-1 immunotherapeutic nivolumab in pediatric patients with relapsed/refractory cancers with elevated TMB and/or MMRD. The authors found that nivolumab was well tolerated, with most patients experiencing grade ≤ 2 treatment-related adverse events (TRAE) and only one patient discontinuing treatment due to grade 3 pancreatitis. A delayed immune response led to an initial overall response rate (ORR) of 20%, however the ORR increased to 50% after the trial ended, with 30% of patients achieving complete response and 20% of patients demonstrating partial response. At a...
Skip Nav Destination
Article navigation
1 December 2023
Highlights|
December 01 2023
Selected Articles from This Issue
Online ISSN: 1557-3265
Print ISSN: 1078-0432
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
Clin Cancer Res (2023) 29 (23): 4699.
- Views Icon Views
- Share Icon Share
-
Tools Icon
Tools
- Search Site
-
Article Versions Icon
Versions
- Version of Record December 1 2023
Citation
Selected Articles from This Issue. Clin Cancer Res 1 December 2023; 29 (23): 4699. https://doi.org/10.1158/1078-0432.CCR-29-23-HI
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Pay-Per-View 24-Hour Access
$50.00
109
Views
Citing articles via
Advertisement